SENSOME
21.6.2021 08:02:06 CEST | Business Wire | Press release
Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today that it has been granted a Breakthrough Device designation by the Center of Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for its Clotild® Smart Guidewire System designed to improve the treatment of ischemic stroke patients.
Acute ischemic stroke, a leading cause of long-term disability, can be treated by removing the clot blocking the brain blood vessel using mechanical thrombectomy devices, which are guided from the groin over a wire to the blockage. To improve patient prognosis, the clot needs to be removed as fast as possible. Today, without knowledge of the clot’s characteristics, the clot can only be removed on the first attempt in one out of three cases. Clotild® Smart Guidewire System integrating Sensome’s AI-powered tissue sensor enables the guidewire to provide physicians with critical information on the clot.
The FDA Breakthrough Device Program is intended to help patients receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. As part of this program, the FDA will provide Sensome with priority review and interactive communication on its path from device development to commercialization.
“This is a tremendous recognition by FDA that will boost our efforts to bringing Clotild® to patients in the US,” indicates Franz Bozsak, CEO and co-founder of Sensome, “The first-in-human clinical trial of Clotild® is expected to start later this year outside the United States, which will take our device one step closer to improving care for ischemic stroke patients around the world.”
About Sensome
Sensome, a spin-off from CNRS and Ecole polytechnique (France), has developed a revolutionary sensor technology that turns invasive medical devices into connected healthcare devices. The company’s sensing technology combines impedance-based micro-sensors with machine learning algorithms to instantly identify biological tissues with unequaled predictive reliability. Its first application is the Clotild®
connected guidewire for the treatment of ischemic stroke. Sensome's sensor technology can be deployed in multiple other medical fields, such as interventional cardiology and oncology.
www.sensome.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210620005074/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Goku Technologies Chooses SS&C for Fund Services2.9.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Singapore Goku Technologies Pte. Ltd., an AI-driven quantitative investment manager, has chosen SS&C as its fund services provider. The firm, with offices in Shanghai and Singapore, employs systematic trading strategies to invest in equities across Asia, with USD4 billion in assets under management. SS&C GlobeOp will provide fund administration services for the Goku Technologies Master Fund. The fund operates a high-volume trading strategy with substantial daily trading activity. SS&C will support the fund through a comprehensive suite of services including fund accounting and investor services, helping Goku Technologies build a scalable operating model. “As our business has grown, so have our demands on our trading and operational framework,” said Ken Chung, CEO of Singapore Goku Technologies. “We are building an institutional quality operations infrastructure, so we needed a provider capable of supporting a high-vol
Boomi Delivers the Critical Infrastructure That Brings Control to Enterprise AI2.9.2026 03:00:00 CEST | Press release
Govern AI agents, optimize token spend, and mitigate security risk to operationalize AI at scale Boomi, the data activation company for AI, today announced major platform innovations designed to solve critical barriers to enterprise AI adoption. At the core of these updates is Boomi’s Agent Control Plane, AI-native infrastructure that securely connects AI agents to core business systems, provides governance over agent activity, and controls runaway AI costs. This critical infrastructure runs flexibly across public cloud, the customer’s own cloud (VPC), or on-premises, directly supporting data and digital sovereignty, and giving organizations greater operational control over their AI estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901851538/en/ Boomi Delivers the Critical Infrastructure That Brings Control to Enterprise AI Key Takeaways Boomi’s Agent Control Plane provides the critical AI-native infrastructure that
Meraki Capital Launches Tessero Across Six European Markets Following Landmark Hays Acquisition1.9.2026 22:36:00 CEST | Press release
Meraki Capital has launched Tessero,a new European specialist recruitment group created from the six former Hays plc businesses it acquired earlier this summer. Launching simultaneously across Sweden, Denmark, Hungary, Romania, Luxembourg and Czechia, Tessero brings six established recruitment businesses together under one independent European brand, creating an international platform with experienced teams, existing clients and active candidate networks from day one. The launch follows one of the most significant transactions in Meraki Capital’s history and the completion of a major transition programme across all six countries within weeks of the acquisition. 130 employees will now operate under the Tessero brand, with established country leadership teams remaining in place and continuing to lead their respective markets. Gary Elden OBE, CEO of Meraki Capital and Director of Tessero, said: “Tessero launches with something that normally takes years to build: established businesses, ex
SBC Medical to Participate in Several Upcoming Investor Conferences in September 20261.9.2026 19:35:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced its participation in several upcoming investor conferences in September 2026. SBC Medical will conduct presentations and one-on-one meetings with institutional investors. Below is a summary of the Company’s scheduled participation in upcoming investor conferences: H.C. Wainwright 28th Annual Global Investment Conference Date: September 14 2026 Format: In-person (NY) Registration: https://my.ct.events/register.aspx?meid=cff43623-9e9f-45d4-bbc3-ee19e9c372c1&rpid=a667ca45-171e-4306-98eb-c466e8b7e6c1 ArcStone Kingswood Growth Summit 2026 Date: September 16 2026 Format: In-person (Toronto) Registration:https://www.meetmax.com/sched/event_144037/investor_reg_new.html?attendee_role_id=ARCSTONE_ATTENDEE CLSA 33rd Investors’ Forum 2026 Date: September 21, 2026 Format: In-person (Hong K
Crimson Moon Available Now, Bringing Heavy-Metal Gothic Action to Solo and Co-op Players on PC, PlayStation 5, and Xbox Series X|S1.9.2026 19:00:00 CEST | Press release
ProbablyMonsters’ action-adventure RPG offers blood-soaked combat, monstrous showdowns, and deep replay value for $19.99 USD ProbablyMonsters, an independent video game company creating original AA games with AAA sensibilities, today launched Crimson Moon on PC via Steam and Epic Game Store, PlayStation 5, and Xbox Series X|S for $19.99 USD. A $29.99 USD Deluxe Edition is also available and includes an exclusive armor set, weapon cosmetic, and upcoming game expansion. Watch the official Crimson Moon launch trailer on YouTube to see the game’s gothic heavy-metal power fantasy, crafted for both solo and co-op players, in action. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901064893/en/ Crimson Moon is a gothic high renaissance action-adventure RPG built around intense, replayable missions that blend brutal precision with deep character progression. Players take on the role of the Nephilim, powerful human-angel hybrids bo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom